Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRT for Residual Lesions in NSCLC Responders to Immunotherapy
NCT05111197Phase 3Unknown
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Overall Survival at 12 months. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05111197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111197.